The online version of this article (doi:10.1186/s13054-017-1899-3) contains supplementary material, which is available to authorized users.
Burn patients are prone to infections which often necessitate broad antibiotic coverage. Vancomycin is a common antibiotic after burn injury and is administered alone (V), or in combination with imipenem-cilastin (V/IC) or piperacillin-tazobactam (V/PT). Sparse reports indicate that the combination V/PT is associated with increased renal dysfunction. The purpose of this study was to evaluate the short-term impact of the three antibiotic administration types on renal dysfunction.
All pediatric and adult patients admitted to our centers between 2004 and 2016 with a burn injury were included in this retrospective review if they met the criteria of exposition to either V, V/IC, or V/PT for at least 48 h, had normal baseline creatinine, and no pre-existing renal dysfunction. Creatinine was monitored for 7 days after initial exposure; the absolute and relative increase was calculated, and patient renal outcomes were classified according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria depending on creatinine increases and estimated creatinine clearance. Secondary endpoints (demographic and clinical data, incidences of septicemia, and renal replacement therapy) were analyzed. Antibiotic doses were modeled in logistic and linear multivariable regression models to predict categorical KDIGO events and relative creatinine increase.
Out of 1449 patients who were screened, 718 met the inclusion criteria, 246 were adults, and 472 were children. Between the study cohorts V, V/IC, and V/PT, patient characteristics at admission were comparable. V/PT administration was associated with a statistically higher serum creatinine, and lower creatinine clearance compared to patients receiving V alone or V/IC in adults and children after burn injury. The incidence of KDIGO stages 1, 2, and 3 was higher after V/PT treatment. In children, the incidence of KDIGO stage 3 following administration of V/PT was greater than after V/IC. In adults, the incidence of renal replacement therapy was higher after V/PT compared with V or V/IC. Multivariate modeling demonstrated that V/PT is an independent predictor of renal dysfunction.
Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in pediatric and adult burn patients when compared to vancomycin alone or vancomycin plus imipenem-cilastin. The mechanism of this increased nephrotoxicity remains elusive and warrants further scientific evaluation.
Chrysopoulo MT, Jeschke MG, Dziewulski P, Barrow RE, Herndon DN. Acute renal dysfunction in severely burned adults. J Trauma Acute Care Surg. 1999;46(1):141–4. CrossRef
Weinstein RA, Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848–54. CrossRef
Williams FN, Herndon DN, Hawkins HK, Lee JO, Cox RA, Kulp GA, et al. The leading causes of death after burn injury in a single pediatric burn center. Crit Care. 2009;13(6):1. CrossRef
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–e55.
Buckley MM, Brogden RN, Barradell LB, Goa KL. Imipenem/cilastatin. Drugs. 1992;44(3):408–44. CrossRef
Joly-Guillou M-L, Kempf M, Cavallo J-D, Chomarat M, Dubreuil L, Maugein J, et al. Comparative in vitro activity of meropenem, imipenem and piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infect Dis. 2010;10:72. CrossRefPubMedPubMedCentral
Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacother J Hum Pharmacol Drug Ther. 2014;34(7):670–6. CrossRef
Gomes DM, Smotherman C, Birch A, Dupree L, Della Vecchia BJ, Kraemer DF, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacother J Hum Pharmacol Drug Ther. 2014;34(7):662–9. CrossRef
Ali A, Herndon DN, Mamachen A, Hasan S, Andersen CR, Grogans R-J, et al. Propranolol attenuates hemorrhage and accelerates wound healing in severely burned adults. Crit. Care Lond. Engl. 2015;19:217.
Léger F, Bouissou F, Coulais Y, Tafani M, Chatelut E. Estimation of glomerular filtration rate in children. Pediatr Nephrol Berl Ger. 2002;17(11):903–7. CrossRef
Hellwig T, Hammerquist R, Loecker B, Shields J. 301: retrospective evaluation of the incidence of vancomycin and/or piperacillin-tazobactam induced acute renal failure. Crit Care Med. 2011;39(12):79.
Roy AK, Mc Gorrian C, Treacy C, Kavanaugh E, Brennan A, Mahon NG, et al. A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure. Cardiorenal Med. 2013;3(1):26–37. CrossRefPubMedPubMedCentral
Gupta A, Biyani M, Khaira A. Vancomycin nephrotoxicity: myths and facts. Neth J Med. 2011;69(9):379–83. PubMed
Min E, Box K, Lane J, Sanchez J, Coimbra R, Doucet J, et al. 714: acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam. Crit Care Med. 2011;39(12):200.
Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. Med Toxicol Adverse Drug Exp. 1988;3(5):376–86. PubMed
Moncrief JA, Switzer WE, Order SE, Mills Jr W, Lindberg RB. The successful control of burn wound sepsis. J Trauma Acute Care Surg. 1965;5(5):601–16. CrossRef
- Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients
David N. Herndon
Karel D. Capek
Ludwik K. Branski
Charles D. Voigt
Elizabeth A. Killion
Andrew De Crescenzo
Ronald P. Mlcak
Michael P. Kinsky
Celeste C. Finnerty
William B. Norbury
- BioMed Central
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II